# Organoid Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/organoid-sciences

- Industry: Biotechnology
- Headquarters: Seongnam, South Korea
- Website: www.organoidrx.com
- Total disclosed funding: $39M
- Latest round: Series B (Jan 27, 2022)
- Investors on record: 10

## About

Based in Seongnam, South Korea, and founded in 2018, Organoid Sciences operates as a biotechnology company that develops new drugs for incurable disease by by utilizing organoids, which is a type of stem cell that can reproduce human organs. In 2020, Organoid Sciences was selected for stem cell regeneration medical project by the Ministry of Health and Welfare. The company's current CEO is Jongman Yu. 

Organoid Sciences engages in the R&D of drug development platform for treating incurable diseases. Organoid Sciences uses organoid based regeneration technology that can reproduce human organs such as pancreases, liver, etc. The company has also developed technologies for ADIO platform based immune assessment and infectious disease analysis through microbiome therapy.

## Funding rounds

- Series B, Jan 27, 2022, $17M — AJU IB Investment, LB Investment, Atinum Investment, Company K Partners, E&Venture Partners
- Series B, Nov 22, 2021, $15M — Korea Development Bank, Asan Foundation, WONIK Investment Partners, Time Folio Asset Management, Dongwha Pharmaceutical
- Series A, Mar 24, 2020, $6.5M — AJU IB Investment, LB Investment, Atinum Investment, Company K Partners

## Investors

- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series A, Series B
- LB Investment (https://capitalatlas.ai/funds/lb-investment) — Series A, Series B
- Atinum Investment (https://capitalatlas.ai/funds/atinum-investment) — Series A, Series B
- Company K Partners (https://capitalatlas.ai/funds/company-k-partners) — Series A, Series B
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series B
- Asan Foundation — Series B
- WONIK Investment Partners (https://capitalatlas.ai/funds/wonik-investment-partners) — Series B
- Time Folio Asset Management — Series B
- Dongwha Pharmaceutical — Series B
- E&Venture Partners (https://capitalatlas.ai/funds/e-venture-partners) — Series B